This Company Wants to Rewrite the Future of Genetic Disease

Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can't do.

This Company Wants to Rewrite the Future of Genetic Disease
Tessera Therapeutics is developing a new class of gene editors capable of precisely plugging in long stretches of DNA—something that Crispr can't do.
Read More